These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35768912)

  • 1. Addressing bedaquiline treatment interruptions in the treatment of drug-resistant TB.
    Kambili C; Rossenu S; Hoetelmans RMW; Birmingham E; Bakare N
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):671-677. PubMed ID: 35768912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A modeling-based proposal for safe and efficacious reintroduction of bedaquiline after dose interruption: A population pharmacokinetics study.
    Keutzer L; Akhondipour Salehabad Y; Davies Forsman L; Simonsson USH
    CPT Pharmacometrics Syst Pharmacol; 2022 May; 11(5):628-639. PubMed ID: 35102712
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimized Loading Dose Strategies for Bedaquiline When Restarting Interrupted Drug-Resistant Tuberculosis Treatment.
    Koele SE; van Beek SW; Maartens G; Brust JCM; Svensson EM
    Antimicrob Agents Chemother; 2022 Mar; 66(3):e0174921. PubMed ID: 35007141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Modeling the impact of bedaquiline treatment strategies on the multidrug-resistant tuberculosis burden in India.
    Mehra M; Kambili C; Potluri R; Rhines A; Singh V; Thomas A
    Int J Tuberc Lung Dis; 2017 Aug; 21(8):902-909. PubMed ID: 28786799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Primary bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Moe S; Rekart ML; Hernandez D; Sholpan A; Ismailov A; Oluya M; Bayniyazova A; Zinaida T; Nargiza P; Gomez-Restrepo C; Sitali N; Sinha A
    Int J Tuberc Lung Dis; 2023 May; 27(5):381-386. PubMed ID: 37143220
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
    Doan TN; Cao P; Emeto TI; McCaw JM; McBryde ES
    Antimicrob Agents Chemother; 2018 Dec; 62(12):. PubMed ID: 30249697
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients.
    Barvaliya SV; Desai MK; Panchal JR; Solanki RN
    Indian J Tuberc; 2020 Apr; 67(2):222-230. PubMed ID: 32553316
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of bedaquiline regimen on the treatment success rates of multidrug-resistant tuberculosis patients in Egypt.
    Afifi M; Amin W; Helal D; Ashmawy R; El-Maradny YA; Khalifa N; Ghazy RM
    Sci Rep; 2024 Jul; 14(1):16247. PubMed ID: 39009633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Acquisition of clofazimine resistance following bedaquiline treatment for multidrug-resistant tuberculosis.
    Liu Y; Gao J; Du J; Shu W; Wang L; Wang Y; Xue Z; Li L; Xu S; Pang Y
    Int J Infect Dis; 2021 Jan; 102():392-396. PubMed ID: 33130209
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effectiveness and safety of bedaquiline under conditional access program for treatment of drug-resistant tuberculosis in India: An interim analysis.
    Salhotra VS; Sachdeva KS; Kshirsagar N; Parmar M; Ramachandran R; Padmapriyadarsini C; Patel Y; Mehandru L; Jaju J; Ponnuraja C; Gupta M; Kalaiselvan V; Shamim A; Khaparde S; Swaminathan S;
    Indian J Tuberc; 2020 Jan; 67(1):29-37. PubMed ID: 32192613
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Long-term plasma pharmacokinetics of bedaquiline for multidrug- and extensively drug-resistant tuberculosis.
    Perrineau S; Lachâtre M; Lê MP; Rioux C; Loubet P; Fréchet-Jachym M; Gonzales MC; Grall N; Bouvet E; Veziris N; Yazdanpanah Y; Peytavin G
    Int J Tuberc Lung Dis; 2019 Jan; 23(1):99-104. PubMed ID: 30674381
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Initial experience of bedaquiline implementation under the National TB Programme at NITRD, Delhi, India.
    Sarin R; Singla N; Vohra V; Singla R; Puri MM; Munjal S; Khalid UK; Myneedu VP; Kumar Verma A; Mathuria KK
    Indian J Tuberc; 2019 Jan; 66(1):209-213. PubMed ID: 30878071
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative Efficacy of the Novel Diarylquinoline TBAJ-876 and Bedaquiline against a Resistant
    Almeida D; Converse PJ; Li SY; Upton AM; Fotouhi N; Nuermberger EL
    Antimicrob Agents Chemother; 2021 Nov; 65(12):e0141221. PubMed ID: 34570644
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of Bedaquiline Use beyond Six Months in Patients with Multidrug-Resistant Tuberculosis.
    Trevisi L; Hernán MA; Mitnick CD; Khan U; Seung KJ; Rich ML; Bastard M; Huerga H; Melikyan N; Atwood SA; Avaliani Z; Llanos F; Manzur-Ul-Alam M; Zarli K; Binegdie AB; Adnan S; Melikyan A; Gelin A; Isani AK; Vetushko D; Daugarina Z; Nkundanyirazo P; Putri FA; Vilbrun C; Khan M; Hewison C; Khan PY; Franke MF
    Am J Respir Crit Care Med; 2023 Jun; 207(11):1525-1532. PubMed ID: 36802336
    [No Abstract]   [Full Text] [Related]  

  • 15. Examples of bedaquiline introduction for the management of multidrug-resistant tuberculosis in five countries.
    Guglielmetti L; Hewison C; Avaliani Z; Hughes J; Kiria N; Lomtadze N; Ndjeka N; Setkina S; Shabangu A; Sikhondze W; Skrahina A; Veziris N; Furin J
    Int J Tuberc Lung Dis; 2017 Feb; 21(2):167-174. PubMed ID: 28234080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Exposure-safety analysis of QTc interval and transaminase levels following bedaquiline administration in patients with drug-resistant tuberculosis.
    Tanneau L; Svensson EM; Rossenu S; Karlsson MO
    CPT Pharmacometrics Syst Pharmacol; 2021 Dec; 10(12):1538-1549. PubMed ID: 34626526
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Reduced Susceptibility of Mycobacterium tuberculosis to Bedaquiline During Antituberculosis Treatment and Its Correlation With Clinical Outcomes in China.
    Liu Y; Gao M; Du J; Wang L; Gao J; Shu W; Wang Y; Xue Z; Li L; Pang Y
    Clin Infect Dis; 2021 Nov; 73(9):e3391-e3397. PubMed ID: 32667984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Global programmatic use of bedaquiline and delamanid for the treatment of multidrug-resistant tuberculosis.
    Cox V; Brigden G; Crespo RH; Lessem E; Lynch S; Rich ML; Waning B; Furin J
    Int J Tuberc Lung Dis; 2018 Apr; 22(4):407-412. PubMed ID: 29562988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bedaquiline: A New Hope for Shorter and Better Anti-Tuberculosis Regimens.
    Riccardi N; Del Puente F; Magnè F; Taramasso L; Di Biagio A
    Recent Pat Antiinfect Drug Discov; 2018; 13(1):3-11. PubMed ID: 28625141
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acquired bedaquiline resistance in Karakalpakstan, Uzbekistan.
    Nair P; Hasan T; Zaw KK; Allamuratova S; Ismailov A; Mendonca P; Bekbaev Z; Parpieva N; Singh J; Sitali N; Bermudez-Aza E; Sinha A
    Int J Tuberc Lung Dis; 2022 Jul; 26(7):658-663. PubMed ID: 35768925
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.